Follow Us
HIV Treatment and Medical Care

Viread (Tenofovir Disoproxil Fumarate)

The Latest

An Overview of Viread (Tenofovir) Img

An Overview of Viread (Tenofovir)

Brand Name: Viread Other Names: TDF, tenofovir DF Drug Class: Nucleoside Reverse Transcriptase Inhibitors

With the Public Attuned to Drug Pricing, Advocates Request Affordable Rate for New HIV Drug Img

With the Public Attuned to Drug Pricing, Advocates Request Affordable Rate for New HIV Drug

The Fair Pricing Coalition says that patients, insurers and public programs shouldn't have to pay higher costs for a next-generation HIV treatment could make combination therapy less toxic.

Promo Image


Brand name: Viread

Generic name: tenofovir disoproxil fumarate (tenofovir), or TDF

Class: Nucleotide reverse transcriptase inhibitor(nucleotide, NtRTI, or nuke)

Manufacturer: Gilead Sciences, Inc.,, (800) GILEAD-5 (445-3235)

AWP: $...

Promo Image

Tenofovir (Viread)

What Is Tenofovir? Who Should Take Tenofovir? What About Drug Resistance? How Is Tenofovir Taken? What Are the Side Effects? How Does Tenofovir React With Other Drugs?

What Is Tenofovir?

Tenofovir (Viread), also called bis-POC PMPA, is ...

Promo Image

Viread (Tenofovir)

Viread is supplied in 300-mg tablets that are almond shaped, light blue film coated, and embossed with "GILEAD" and "4331" on one side and with "300" on the other side.

Background Coformulations Dose Food Restrictions Storage Patient Assis...

Promo Image

Tenofovir DF on the Horizon

A new drug application for Tenofovir disoproxil fumarate (Tenofovir DF) has been filed with the Food and Drug Administration by Gilead Sciences. Tenofovir DF, also known as PMPA, could be approved within the next six months.

Tenofovir DF is an inves...

Promo Image

Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26

On October 3 the FDA's Antiviral Drugs Advisory Committee will hold a public hearing on tenofovir (full chemical name tenofovir disoproxil fumarate, or tenofovir DF; new brand name Viread™, an antiretroviral developed by Gilead Sciences and currently...

Promo Image

Tenofovir: Gilead Applies for Approval; Expanded Access Liberalized

Tenofovir, Gilead Sciences' candidate reverse transcriptase inhibitor, could be approved in about six months. In an unexpected move, the company announced May 1 that it had filed a New Drug Application with the FDA. After approval, tenofovir could be...

Promo Image

PMPA: Experimental Drug That Completely Protects Monkeys Exposed to SIV

This is a statement from the National Institutes of Health (NIH) concerning an experimental drug that completely protects monkeys exposed to SIV.

An experimental drug called PMPA given to 25 macaque monkeys up to a day after they were exposed to sim...